Mohammed Tanjimur Rahman

Mohammed Tanjimur Rahman

Auto-generated profile, based on publicly available information

Mohammed Tanjimur Rahman

Department of Obstetrics and Gynecology, Shimane University School of Medicine, Izumo, Shimane 6938501, Japan

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2012 in Laboratory Investigation
Verified
Journal Article
Closed access
AKAtsuko Katagiri
Atsuko Katagiri
KNKentaro Nakayama
Kentaro Nakayama
MRMohammed Tanjimur Rahman
Mohammed Tanjimur Rahman
MRMunmun Rahman
Munmun Rahman
HKHiroshi Katagiri
Hiroshi Katagiri
KMKohji Miyazaki
Kohji Miyazaki

1 December 2018 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
MRMohammed T. Rahman
Mohammed T. Rahman
Chaitali GhoshChaitali Ghosh
Chaitali Ghosh
MHMohammed Hossain
Mohammed Hossain
DLDebra Linfield
Debra Linfield
Fariba RezaeeFariba Rezaee
Fariba Rezaee
ABAnette H.H. van Boxel-Dezaire
Anette H.H. van Boxel-Dezaire

1 October 2012 in American Journal of Clinical Pathology
Verified
Journal Article
Open access
PDF file
MRMohammed Tanjimur Rahman
Mohammed Tanjimur Rahman
KNKentaro Nakayama
Kentaro Nakayama
MRMunmun Rahman
Munmun Rahman
HKHiroshi Katagiri
Hiroshi Katagiri
AKAtsuko Katagiri
Atsuko Katagiri
KMKohji Miyazaki
Kohji Miyazaki
This study examined the clinical significance of Notch3 expression and assessed its usefulness as a potential therapeutic target in chemoresistant ov

5 July 2011 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
KIK Iida
K Iida
KNKentaro Nakayama
Kentaro Nakayama
MRM T Rahman
M T Rahman
MRM Rahman
M Rahman
MIM Ishikawa
M Ishikawa
KMK Miyazaki
K Miyazaki
The aim of this study was to investigate the patterns of epidermal growth factor receptor (EGFR) overexpression, EGFR gene amplification, and the presence of activating mutations in the tyrosine kinase domain of this gene in squamous cell carcinomas and adenocarcinomas/adenosquamous carcinomas of the uterine cervix. The EGFR expression, amplification, and mutation in cervical carcinomas were assessed by immunohistochemistry, fluorescence in situ hybridisation, and PCR–SSCP, respectively, and correlated with clinical data collected by a retrospective chart review. A functional assessment was performed by inactivating EGFR in cervical cancer cells with the potent inhibitor AG1478. Immunohistochemical analysis revealed that 6 out of 59 (10.2%) cervical squamous cell carcinomas showed significant amplification of the EGFR locus, whereas none of the 52 adeno/adenosquamous cell carcinomas had detectable EGFR amplification (P<0.05). The EGFR amplification significantly correlated with shorter overall survival (P=0.001) in cervical squamous cell carcinomas. Multivariate analysis showed that EGFR gene amplification was an independent prognostic factor for overall survival (P=0.011). None of the squamous cell carcinomas (0%: 0 out of 32) had detectable oncogenic mutations in EGFR exons 18 through 21. The frequencies of KRAS and BRAF mutations were very low in both squamous and adeno/adenosquamous cell carcinomas. Sensitivity of cervical cancer cells to AG1478 depended on the presence of EGFR overexpression. AG1478-induced EGFR inactivation in cell lines with EGFR overexpression significantly suppressed tumour development and progression in a mouse xenograft model. Our data suggest that EGFR signalling is important in a subset of cervical squamous cell carcinomas and that anti-EGFR therapy may benefit patients who carry the 7p11.2 amplicon in their tumours.

26 November 2015 in International Journal of Oncology
Verified
Journal Article
Open access
PDF file
KNKentaro Nakayama
Kentaro Nakayama
MRMohammed Tanjimur Rahman
Mohammed Tanjimur Rahman
MRMunmun Rahman
Munmun Rahman
KNKohei Nakamura
Kohei Nakamura
MIMasako Ishikawa
Masako Ishikawa
SKSatoru Kyo
Satoru Kyo
The clinicopathological significance of amplification was investigated of the gene encoding cyclin E (CCNE1) and we assessed whether CCNE1 was a potential target in endometrioid endometrial carcinomas. CCNE1 amplification and CCNE1 or F-box and WD repeat domain-containing 7 (FBXW7) expression in endometrial endometrioid carcinoma was assessed by immunohistochemistry and fluorescence in situ hybridization. CCNE1 knockdown by small interfering RNA (siRNA) was used to assess the CCNE1 function. The results showed that CCNE1 amplification was present in 9 (8.3%) of 108 endometrial carcinomas. CCNE1 amplification was correlated with high histological grade (Grade 3; p=0.0087) and lymphovascular space invasion (p=0.0258). No significant association was observed between CCNE1 amplification and FIGO stage (p=0.851), lymph node metastasis (p=0.078), body mass index (p=0.265), deep myometrial invasion (p=0.256), menopausal status (p=0.289) or patient age (p=0.0817). CCNE1 amplification was significantly correlated with shorter progression-free and overall survival (p=0.0081 and 0.0073, respectively). CCNE1 protein expression or loss of FBXW7 expression in endometrial endometrioid carcinoma tended to be correlated with shorter progression-free and overall survival; however, this difference was not statistically significant. Multivariate analysis showed that CCNE1 amplification was an independent prognostic factor for overall survival but not for progression-free survival (P=0.0454 and 0.2175, respectively). Profound growth inhibition was observed in siRNA-transfected cancer cells with endogenous CCNE1 overexpression compared with that in cancer cells having low CCNE1 expression. CCNE1 amplification was independent of p53, HER2, MLH1 and ARID1A expression but dependent on PTEN expression in endometrial carcinomas. These findings indicated that CCNE1 amplification was critical for the survival of endometrial endometrioid carcinomas. Furthermore, the effects of CCNE1 knockdown were dependent on the CCNE1 expression status, suggesting that CCNE1-targeted therapy may be beneficial for patients with endometrial endometrioid carcinoma having CCNE1 amplification.

23 January 2020 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
MRMohammed Tanjimur Rahman
Mohammed Tanjimur Rahman
SMSantoshi Muppala
Santoshi Muppala
JWJiahui Wu
Jiahui Wu
IKIrene Krukovets
Irene Krukovets
DSDmitry Solovjev
Dmitry Solovjev
OAOlga Stenina Adognravi
Olga Stenina Adognravi
Thrombospondin-4 (TSP-4) attracted renewed attention recently as a result of assignment of new functions to this matricellular protein in cardiovascular, muscular, and nervous systems. We have previously reported that TSP-4 promotes local vascular inflammation in a mouse atherosclerosis model. A common variant of TSP-4, P387-TSP-4, was associated with increased cardiovascular disease risk in human population studies. In a mouse atherosclerosis model, TSP-4 had profound effect on accumulation of macrophages in lesions, which prompted us to examine its effects on macrophages in more detail. We examined the effects of A387-TSP-4 and P387-TSP-4 on mouse macrophages in cell culture and in vivo in the model of LPS-induced peritonitis. In tissues and in cell culture, TSP-4 expression was associated with inflammation: TSP-4 expression was upregulated in peritoneal tissues in LPS-induced peritonitis, and pro-inflammatory signals, INFγ, GM-CSF, and LPS, induced TSP-4 expression in macrophages in vivo and in cell culture. Deficiency in TSP-4 in macrophages from Thbs4−/− mice reduced the expression of pro-inflammatory macrophage markers, suggesting that TSP-4 facilitates macrophage differentiation into a pro-inflammatory phenotype. Expression of TSP-4, especially more active P387-TSP-4, was associated with higher cellular apoptosis. Cultured macrophages displayed increased adhesion to TSP-4 and reduced migration in presence of TSP-4, and these responses were further increased with P387 variant. We concluded that TSP-4 expression in macrophages increases their accumulation in tissues during the acute inflammatory process and supports macrophage differentiation into a pro-inflammatory phenotype. In a model of acute inflammation, TSP-4 supports pro-inflammatory macrophage apoptosis, a response that is closely related to their pro-inflammatory activity and release of pro-inflammatory signals. P387-TSP-4 was found to be the more active form of TSP-4 in all examined functions.